ERCC1 (SPM243) Antibody sc-56386 from Santa Cruz Biotechnology, Inc. | Biocompare.com

Supplier Images

ERCC1 (SPM243) Antibody

Be the first to write a review!

Citations:

Supplier Page from
Santa Cruz Biotechnology, Inc. for
ERCC1 (SPM243) Antibody

The ERCC1 (SPM243) Antibody from Santa Cruz Biotechnology, Inc. is a Mouse Monoclonal antibody to ERCC1. This antibody recognizes Homo Sapiens, Human, and Rat antigen. The ERCC1 (SPM243) Antibody has been shown to work in the following applications: EIA, Immunoassay, Precipitation, ELISA, Immunofluorescence, Immunohistochemistry - fixed, Immunoprecipitation, and Western Blot.

Description

ERCC1 (SPM243)

Product Specs
ItemERCC1 (SPM243) Antibody
CompanySanta Cruz Biotechnology, Inc.
Price $316.00Supplier Page View Company Product Page
Catalog Numbersc-56386
NCBI Gene AliasesCOFS4, RAD10, UV20
Antibody TypePrimary Antibodies
CloneSPM243
Quantity50 µg/0.5 ml
Reactivityhuman, rat
ApplicationsWB, IP, IF, IHC(P), ELISA
FormatPurified
Hostmouse
Conjugate/TagUnconjugated
ClonalityMonoclonal
NCBI Full Gene NameERCC excision repair 1, endonuclease non-catalytic subunit
TargetERCC1
IsotypeIgG2b

Add to Compare List

Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapyJournal of cancer research and therapeuticsJanuary 1, 2018Zhou J, Wang D, Zheng JH, Wang Z, Xie B, Zhang WM.

(2) Databases for technical aspects of immunohistochemistryJournal of toxicologic pathologyJanuary 1, 2017Furukawa S, Nagaike M, Ozaki K.

(3) A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance markerCancer chemotherapy and pharmacologyMarch 1, 2013Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, Harada K, Miyamoto H, Sato Y, Takahashi Y, et al.

(4) Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancerJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerApril 1, 2010Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G.

(5) In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapyCancer investigationFebruary 1, 2010Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, et al.

Be the First to Write a Review!